Badar Anwar, MD
Internal Medicine · Henderson, NVNPI 1861443640
Payments from drug & device makers
Across 339 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$724
- AbbVie$662
- Pfizer$479
- Astellas Pharma US Inc$277
- Amarin Pharma, Inc.$226
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,69897%
- Education$1483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $1,439 |
| Amgen(2 entities) | 38 | $724 |
| AbbVie(2 entities) | 52 | $662 |
| Pfizer | 30 | $479 |
| Astellas Pharma US Inc | 14 | $277 |
| Amarin Pharma, Inc. | 21 | $226 |
| Novo Nordisk | 12 | $212 |
| Lilly USA, LLC | 11 | $201 |
| Merck | 12 | $195 |
| Kowa Pharmaceuticals America, Inc. | 9 | $155 |
| Otsuka America Pharmaceutical, Inc. | 2 | $152 |
| Abbott | 5 | $129 |
| Boehringer Ingelheim | 7 | $109 |
| Novartis | 5 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Johnson & Johnson | 7 | $97 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Bayer | 3 | $56 |
| Exact Sciences | 3 | $55 |
| Bausch Health US, LLC | 3 | $51 |
| GSK | 2 | $45 |
| Dexcom, Inc. | 3 | $45 |
| Eisai Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Genentech USA, Inc. | 2 | $31 |
| Intra-sana Laboratories | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Viiv Healthcare Company | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
How this compares
$5,846 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 451 | $557,844 |
| FarxigaDapagliflozin Propanediol | 139 | $187,490 |
| EliquisApixaban | 129 | $161,013 |
| OzempicSemaglutide | 53 | $99,530 |
| JardianceEmpagliflozin | 50 | $78,469 |
| TrulicityDulaglutide | 36 | $54,809 |
| KerendiaFinerenone | 22 | $39,670 |
| Repatha SyringeEvolocumab | 33 | $36,148 |
| Repatha SureclickEvolocumab | 22 | $24,141 |
| JanuviaSitagliptin Phosphate | 15 | $23,710 |
| InvokanaCanagliflozin | 16 | $23,484 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $23,412 |
| XareltoRivaroxaban | 12 | $17,111 |
| MyrbetriqMirabegron | 15 | $15,492 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $14,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $201 | $612,654487 claims |
| AstraZenecaFarxiga, Symbicort | $1,439 | $202,210170 claims |
| PfizerEliquis, Paxlovid | $479 | $163,871162 claims |
| Novo NordiskOzempic | $212 | $99,53053 claims |
| Boehringer IngelheimJardiance | $109 | $78,46950 claims |
| Johnson & JohnsonInvokana, Xarelto | $97 | $40,59528 claims |
| BayerKerendia | $56 | $39,67022 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $45 | $31,74833 claims |
| MerckJanuvia | $195 | $23,71015 claims |
| Astellas Pharma US IncMyrbetriq | $277 | $15,49215 claims |
| AbbVieSynthroid | $662 | $3,37166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Henderson
- Marigene Salazar SharmaHenderson$2.5M
- Mavis MatsumotoHenderson$1.8M
- Ryan HamptonHenderson$233K
- Justin TerryHenderson$19K
- Sonu BhatiaHenderson$18K
- Russell NeibaurHenderson$15K
- John GarrisonHenderson$14K
- Hossein Akhondi AslHenderson$12K
- Ran JiaHenderson$11K
- Darin BrimhallLas Vegas$39.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.